tirzepatide monograph Zepbound® - Injectable Tirzepatide (Mounjaro) Drug Monograph |

For the current prescription group, the average AUDIT-C score was approximately 5% lower than in the future-prescription group, a statistically significant difference

Retatrutide has shown excellent glycemic improvement in its trials as well, and its GIP and glucagon receptor activity may offer additional benefits for insulin sensitivity that GLP-1-only drugs cannot match

You can also report side effects directly via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

Gastroenterology 160 , 23402353 (2021)

I dont think anyone really knows the mechanism, he says